Does Mebendazole have an effect on cancer? YES!

Mebendazole and Its Mechanisms of Action in Tumor Cells

Mebendazole (MBZ) does not act in just one way: it is considered a “multi-target” drug (multi-target). Based on robust scientific literature (studies in vitro, in vivo and early clinical trials), I detail below the main sites and mechanisms of action of mebendazole in tumor cells:

1. Microtubule destabilization (the primary mechanism)

Just as MBZ interferes with the microtubule dynamics of parasites, studies show that it can also interfere with the microtubule dynamics of tumor cells.

✅ Location: MBZ binds specifically to beta-tubulin in tumor cells, often at the same binding site as colchicine.

✅ The mechanism: Cancer cells need to build microtubules—a kind of cellular “skeleton” and “track”—in order to divide and multiply rapidly. By binding to beta-tubulin, mebendazole prevents the polymerization of these microtubules.

✅ The result: The tumor cell may be unable to complete mitosis (cell division), resulting in cell cycle arrest in the G2/M phase, which often leads to apoptosis or other forms of cell death.

2. Inhibition of angiogenesis (leading to a disruption of the blood supply)

Tumors need to create new blood vessels (angiogenesis) to receive oxygen and glucose and continue growing.

✅ Location: Vascular endothelial growth factor receptors, particularly VEGFR2.

✅ The mechanism: Studies show that MBZ inhibits VEGFR2 signaling and reduces the formation of new capillaries around and within the tumor.

✅ The result: Reduced angiogenesis may contribute to a decreased supply of oxygen and nutrients to the tumor, limiting its growth and potential for spread.

3. Induction of apoptosis (programmed cell death)

Cancer cells are “immortal” because they “turn off” the natural mechanism of cell suicide (apoptosis). Mebendazole helps to reactivate this system.

✅ Location: Mitochondria in tumor cells and proteins of the Bcl-2 family.

✅ The mechanism: MBZ promotes the depolarization of the mitochondrial membrane, stimulating the release of cytochrome c. This activates a cascade of “executioner” enzymes called caspases, particularly caspase-3 and caspase-9.

✅ The result: The activation of caspases triggers an organized process of programmed cell death, leading to the controlled fragmentation of the tumor cell—in a clean manner, without causing excessive inflammation in the surrounding healthy tissues, compared to necrosis.

4. Blocking critical signaling pathways (Hedgehog, BRAF, and MEK)

Some cancers rely on overactive cellular signaling pathways to survive.

✅ Hedgehog (Hh) pathway: It is highly active against cancers such as medulloblastoma, a brain tumor. Mebendazole works by affecting factors associated with this pathway, such as the GLI1 protein, thereby helping to suppress tumor growth.

✅ Kinase inhibition: Preclinical studies suggest that MBZ may modulate signaling pathways related to BRAF, MEK, and other kinases involved in tumor survival. Mutations in these pathways are the “driving force” behind various melanomas and colorectal cancers.

✅ The mechanism: MBZ acts almost like a targeted therapy, inhibiting the phosphorylation of these proteins and reducing signals that promote tumor proliferation.

✅ The result: Slower growth, survival, and adaptability of cancer cells.

5. Reprogramming of the Tumor Microenvironment and Immunity

The metabolic approach emphasizes that cancer is not just a genetic problem, but also a problem related to the cell's surrounding environment.

✅ The mechanism: There is evidence that mebendazole helps polarize macrophages—immune cells—in the tumor microenvironment. Experimental studies suggest that it may promote the polarization of M2-type macrophages—which protect the tumor and promote its growth—into M1-type macrophages, which attack the tumor.

✅ The result: The patient's own immune system becomes more effective at recognizing and fighting malignant cells.

The Perspective of Metabolic and Integrative Oncology

When we follow the “metabolic approach” to understanding cancer, we view mebendazole not only as a cytotoxic agent, but also as a tool with the potential to target multiple biological vulnerabilities of cancer.

Because MBZ crosses the blood-brain barrier and reaches the brain, it has been investigated in several clinical and preclinical studies for glioblastoma, one of the most aggressive brain tumors, and is often used in combination with the standard treatment, temozolomide.

---

⚠️ Clinical note: Although there is a considerable body of scientific literature describing the antitumor mechanisms of mebendazole in experimental models and early clinical studies, conventional oncology still considers it an adjuvant therapy or a therapy under investigation (off-label).

The dosage for cancer is different from that used for parasites; it is generally administered continuously and in higher doses, which requires close medical supervision to monitor liver toxicity (liver function).

It is important to note that most of the mechanisms described above were observed in laboratory studies (in vitro) and in animal models, although definitive confirmation of these effects in humans still depends on larger clinical studies.